The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status

Menopause. 2008 Jan-Feb;15(1):94-7. doi: 10.1097/gme.0b013e318148b98b.

Abstract

Objective: To compare serum 17beta-estradiol (E2), estrone (E1), estrone sulfate, follicle-stimulating hormone, luteinizing hormone, sex hormone-binding globulin, vaginal pH, and the vaginal maturation indices in women using a low-dose transdermal patch releasing 14 microg of E2 per day and a vaginal ring releasing 7.5 microg of E2 per day.

Design: Twenty-four postmenopausal women were randomly assigned to either the patch (n = 12) or the ring (n = 12) for a 12-week study period. Serum E2, E1, estrone sulfate, follicle-stimulating hormone, luteinizing hormone, and sex hormone-binding globulin were measured by immunoassay at baseline and 6 and 12 weeks. Vaginal pH was determined at baseline and 6 and 12 weeks. Vaginal cytologic examinations for vaginal maturation index were done at baseline and 12 weeks.

Results: Twenty women completed the study. The patch significantly increased serum E1 and E2 levels at 6 and 12 weeks (P < 0.01); there was no significant increase in serum E1 and E2 levels with the ring. Both the patch and the ring significantly reduced vaginal pH at 6 (P < 0.001) and 12 (P < 0.001) weeks and significantly reduced the percentage of vaginal parabasal cells at 12 weeks with no significant difference between the two groups. Both preparations increased the proportion of superficial cells; the increase was significant only with the patch (P = 0.04).

Conclusions: A transdermal E2 skin patch releasing 14 microg of E2 per day had an effect on vaginal pH and vaginal maturation indices similar to that of a vaginal E2 ring releasing 7.5 microg of E2 per day. Therefore, this patch is likely to relieve symptoms of vulvovaginal atrophy.

Publication types

  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Administration, Intravaginal
  • Atrophy / drug therapy
  • Atrophy / pathology
  • Drug Delivery Systems / methods
  • Estradiol / administration & dosage*
  • Estrogen Replacement Therapy / methods*
  • Estrogens / administration & dosage*
  • Estrogens / blood*
  • Estrone / analogs & derivatives
  • Estrone / blood
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Luteinizing Hormone / blood
  • Middle Aged
  • Postmenopause / drug effects*
  • Postmenopause / metabolism
  • Prospective Studies
  • Sex Hormone-Binding Globulin / metabolism
  • Vagina / drug effects
  • Vagina / pathology
  • Vaginal Creams, Foams, and Jellies / administration & dosage

Substances

  • Estrogens
  • Sex Hormone-Binding Globulin
  • Vaginal Creams, Foams, and Jellies
  • Estrone
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • estrone sulfate